LONDON, UK – In a significant leap forward for cancer immunotherapy, researchers at King’s College London have illuminated the precise mechanism by which a novel class of antibody treatment reactivates patients’ own immune cells to combat ovarian cancer. This pioneering research, led by Professor Sophia Karagiannis, focuses on an innovative antibody type, IgE, which stands in stark contrast to conventional therapies and offers a beacon of hope for patients facing this challenging disease. The findings, published today in the prestigious journal Nature Communications, not only deepen our understanding of immune responses to therapy but also pave the way for a transformative approach to solid tumour treatment.
For decades, the medical community has grappled with the formidable challenge of ovarian cancer, often dubbed the "silent killer" due to its insidious nature and late-stage diagnosis. Despite advancements in surgery and chemotherapy, prognosis for advanced ovarian cancer remains grim, highlighting an urgent need for more effective and targeted treatments. Immunotherapy, which harnesses the body’s own immune system to fight cancer, has emerged as a promising avenue, yet its success against ovarian cancer has been limited, particularly with the widely used IgG class of antibodies. This new research from King’s College London, however, marks a pivotal moment, introducing an entirely new weapon in the arsenal against this deadly disease.
Battling a Silent Foe: The Challenge of Ovarian Cancer
Ovarian cancer remains one of the most lethal gynaecological cancers globally. Its symptoms are often vague and can be easily mistaken for less serious conditions, leading to diagnoses typically made at advanced stages when the disease has already spread. Standard treatments usually involve aggressive surgery followed by chemotherapy, but recurrence rates are high, and many patients eventually develop resistance to these conventional therapies. The tumour microenvironment in ovarian cancer is notoriously immunosuppressive, actively disarming the body’s natural defences and allowing cancer cells to proliferate unchecked. This inherent ability of ovarian tumours to evade and suppress the immune system has been a major barrier to effective treatment, particularly for immunotherapies designed to amplify immune responses.
The quest for more potent and specific immunotherapies has driven research into various antibody formats. Traditional antibody treatments, predominantly derived from the IgG class, function by flagging cancer cells for destruction or blocking growth signals. While IgG antibodies have revolutionized the treatment of several cancers, their efficacy against ovarian cancer has been underwhelming. This limitation underscored the need for a fundamentally different approach, one capable of penetrating the unique immunological barriers presented by ovarian tumours. It was this unmet clinical need that spurred Professor Karagiannis’s team to explore the untapped potential of IgE antibodies.
Unlocking a Novel Immunological Pathway: The IgE Advantage
The team at King’s College London has distinguished itself as the first in the world to develop a cancer treatment from Immunoglobulin E (IgE), an antibody class previously best known for its role in allergic reactions and defence against parasitic infections. Unlike the more common IgG antibodies, which primarily circulate in the blood and activate immune cells there, IgE antibodies possess a unique biological characteristic: they bind with exceptionally high affinity to specific receptors on immune cells found directly within tissues. This tight, localised binding is crucial, as it allows IgE to exert a more potent and focused effect within the tumour microenvironment, where the immune system is often most compromised.
The biological functions of IgE are multifaceted. In the context of allergies, IgE triggers rapid and robust immune responses, releasing inflammatory mediators that lead to symptoms like swelling and redness. In parasitic infections, IgE mobilizes immune cells to directly attack and expel large pathogens. Professor Karagiannis and her team hypothesised that these powerful, tissue-resident immune-boosting activities of IgE could be re-engineered and harnessed to combat solid cancers. The sheer strength and persistence of IgE’s binding to immune cells, particularly to macrophages and mast cells which are abundant in tumour tissues, suggested a mechanism capable of overcoming the immunosuppressive forces at play in cancers like ovarian cancer.
The specific IgE antibody under investigation, named MOv18, has been meticulously developed to target ovarian cancer cells. The research team embarked on a comprehensive study to unravel MOv18 IgE’s intricate interaction with immune cells from ovarian cancer patients and its broader influence on the complex tumour microenvironment. Their investigations aimed to pinpoint precisely how this novel antibody works to reverse the tumour’s suppressive grip on the immune system, thereby activating a potent anti-cancer response. This deep dive into the molecular and cellular mechanisms is not merely academic; it is foundational for optimizing treatment strategies, identifying patient populations most likely to benefit, and potentially expanding the application of IgE therapy to a wider spectrum of cancers.
From Bench to Bedside: Early Clinical Success and Deeper Insights
The journey of MOv18 IgE has already yielded promising results in early-phase clinical trials, providing a crucial bridge from laboratory discovery to patient benefit. A pioneering phase Ia clinical trial, meticulously designed and executed by King’s researchers at the National Institute for Health and Care Research (NIHR) Guy’s and St Thomas’ Clinical Research Facility, in collaboration with Cancer Research UK’s Centre for Drug Development, offered the first glimpse into MOv18 IgE’s therapeutic potential in humans.
In a particularly compelling case, the trial demonstrated that MOv18 IgE, even at low doses, induced tumour shrinkage in a patient with ovarian cancer who had previously exhausted all conventional treatment options and showed no response to other therapies. This individual success story, while preliminary, provided powerful validation for the IgE platform and served as a significant impetus for the team to delve deeper into the antibody’s exact workings within the complex immune landscape of ovarian cancer. Understanding how this remarkable effect was achieved was critical for advancing the therapy and maximizing its impact.
The recent study, published in Nature Communications, represents this critical next step. It was a multidisciplinary endeavour, spanning King’s College London, Guy’s and St Thomas’ NHS Foundation Trust, the Medical University of Vienna, Fondazione IRCCS Instituto Nazionale dei Tumori in Milan, and SeromYx Systems, Inc. This collaborative effort underscored the global scientific interest and commitment to unlocking the full potential of IgE-based therapies. The researchers set out to meticulously dissect MOv18 IgE’s interactions with various immune cell populations found within ovarian cancer patients, with a particular focus on macrophages.
Unraveling the Mechanism: MOv18 IgE’s Unique Approach to Immune Reversal
At the heart of MOv18 IgE’s mechanism lies its ability to reprogram crucial immune cells within the tumour microenvironment. The study principally investigated macrophages, a type of immune cell that typically plays a vital role in host defence, engulfing pathogens and clearing cellular debris. However, in the context of cancer, these macrophages often become "corrupted." Tumours skillfully manipulate macrophages, suppressing their inherent ability to mount an immune response and instead reprogramming them to support tumour growth, angiogenesis, and metastasis. This subversion of macrophages into "tumour-associated macrophages" (TAMs) is a major mechanism by which cancers establish an immunosuppressive shield, allowing them to evade destruction.
Macrophages: From Tumour Allies to Cancer Fighters
Previous preclinical research in animal models had suggested that MOv18 IgE could activate these corrupted macrophages, driving them back towards an anti-cancer phenotype. To rigorously test this hypothesis in a human context, the research team designed elegant experiments. They first collected macrophages from healthy donors and then exposed these cells to cancerous fluid samples obtained from the peritoneal cavity of ovarian cancer patients – the primary site of ovarian cancer spread. In parallel, they directly isolated macrophages from these patient-derived cancerous fluid samples. All patient samples were collected ethically from Guy’s and St Thomas’ NHS Foundation Trust, ensuring the clinical relevance of their findings.
In both experimental setups, the researchers observed a consistent pattern: ovarian cancer profoundly suppressed the normal immune activity of macrophages. However, the introduction of MOv18 IgE dramatically altered this scenario. They discovered that MOv18 IgE could bind specifically and effectively to these suppressed macrophages, reactivating their anti-tumour functions and enabling them to directly kill ovarian cancer cells. This wasn’t merely a passive binding; it was an active reprogramming, shifting the macrophages from a pro-tumour state to a pro-inflammatory, cancer-fighting state.
Dr. Gabriel Osborn, who conducted this pivotal research during his PhD studies at King’s College London, elaborated on these groundbreaking findings: "We found that in patients, ovarian cancer actively re-programmed macrophages away from normal immune activation. Instead, these corrupted macrophages formed an immunosuppressive web in association with T cells, effectively restricting anti-cancer immunity in patients. Critically, MOv18 IgE induced patient macrophages to not only kill cancer cells but also undergo a highly inflammatory activation, which reversed their suppressive effects on T cells. This study adds vital patient-level information, supporting what we previously observed for MOv18 IgE in the laboratory, and, for the first time, reveals that IgE-driven macrophage stimulation can activate the wider tumour immune system."
Reactivating T-Cell Immunity
The implications of MOv18 IgE’s effect on macrophages extend beyond these cells alone. Through their activation, MOv18 IgE-stimulated macrophages also reversed the immunosuppressive influence they had exerted on other critical immune cells: T cells. T cells are widely recognized as indispensable orchestrators of long-term immune responses against cancer. They are capable of directly recognizing and killing cancer cells and establishing immunological memory, preventing recurrence. However, in many cancers, including ovarian cancer, T cells often become exhausted or suppressed within the tumour microenvironment, rendering them ineffective. By reactivating macrophages and shifting their phenotype, MOv18 IgE effectively removes a significant barrier to T-cell function, allowing these crucial lymphocytes to regain their anti-cancer activity. This synergistic effect, where IgE directly activates macrophages which then indirectly unleash T cells, highlights the sophisticated and multi-pronged approach of this novel therapy.
Patient-Derived Evidence Confirms Lab Findings
To bridge the gap between in vitro laboratory observations and real-world clinical outcomes, the research team then turned their attention to actual tumour biopsies from two patients who had participated in the phase Ia clinical trial. They meticulously analysed two biopsy samples from each patient: one collected before treatment with MOv18 IgE and a second collected after treatment. The analysis of these paired samples revealed compelling evidence consistent with their laboratory findings. Post-treatment biopsies showed a marked increase in the numbers of both macrophages and T cells within the tumour microenvironment. This influx and activation of key immune cells strongly indicated that both macrophages and T cells play a central and collaborative role in the anti-tumour activity observed with MOv18 IgE, providing robust clinical validation for the proposed mechanism.
Expert Perspectives: Pioneers on the Promise of IgE Therapy
The leaders behind this groundbreaking research shared their insights on the significance of these findings and the path forward.
Professor Sophia Karagiannis, Professor of Translational Cancer Immunology and Immunotherapy at King’s College London and the senior author of the study, emphasized the foundational importance of understanding the underlying biology: "Understanding the biology of how a treatment works is essential for bringing treatments closer to patients. We found that immune cells which are otherwise inhibited in the ‘microenvironment’ of the tumour, are directed by IgE to target the cancer cells. While we are still progressing with clinical testing in patients, it is imperative that we continue in our quest towards understanding how MOv18 IgE, and a wider panel of IgE-based antibodies we are studying, harness the immune system in different groups of patients and cancer types." Her statement underscores the commitment to not just developing new drugs, but deeply understanding their interaction with the human body’s complex biological systems.
Dr. Debra Josephs, consultant medical oncologist at Guy’s and St Thomas’ NHS Foundation Trust and a co-author of the study, played a crucial role in developing the preclinical research that guided MOv18 IgE towards clinical testing. She highlighted the ongoing dedication to improving patient outcomes: "Our focus is to deepen our understanding of the immune system and its interaction with cancer, with the goal of discovering better treatments for patients. During the preclinical development of MOv18 IgE, we demonstrated the important role of activation and migration of tumour-associated macrophages into cancer lesions for this antibody treatment to be effective. This research marks an important next step in the development of MOv18 IgE by advancing our understanding of macrophage-mediated mechanisms, thus supporting the therapeutic potential of this novel antibody." Her perspective, bridging the gap between basic science and clinical application, is vital for translating research into tangible patient benefits.
Professor James Spicer, Professor of Experimental Cancer Medicine at King’s College London, consultant in medical oncology at Guy’s and St Thomas’ NHS Foundation Trust, and Chief Clinical Investigator of the MOv18 IgE Phase Ia trial, also a co-author of the study, articulated the broader clinical imperative: "We need to achieve better outcomes for our patients. Clear progress is being made by studying the immune system and the environment in which the cancer grows. In our ongoing research, we are striving to understand how we can capitalise on the power of IgE to develop novel effective treatments, which will complement established IgG antibody drugs used in the clinic." Professor Spicer’s comments highlight the collaborative spirit and the ambition to integrate IgE therapy into the existing landscape of cancer treatments, offering a complementary and potentially superior option where IgG antibodies fall short.
Future Horizons: Expanding the Reach of IgE Antibodies
The successful elucidation of MOv18 IgE’s mechanism of action represents a significant milestone, not just for ovarian cancer patients but for the broader field of cancer immunotherapy. This research confirms that IgE antibodies possess unique properties that allow them to effectively penetrate and reprogram the immunosuppressive tumour microenvironment, a feat that has proven challenging for other antibody classes. The findings open up exciting new avenues for drug development, suggesting that IgE-based therapies could be tailored to target a variety of solid cancers that currently resist conventional immunotherapies.
The next steps for Professor Karagiannis’s team and their collaborators will involve further clinical testing of MOv18 IgE in larger patient cohorts to confirm its efficacy and safety. This will include phase Ib/II trials designed to establish optimal dosing, assess responses across a more diverse patient population, and potentially explore combinations with other existing cancer therapies. Beyond MOv18, the King’s team is actively investigating a wider panel of IgE-based antibodies, each designed to target different cancer types and exploit various immunological pathways. This systematic approach aims to build a robust platform for IgE therapeutics, transforming how solid tumours are treated.
The potential implications are profound. Imagine a future where the unique tissue-binding and potent immune-activating properties of IgE antibodies can be leveraged to overcome resistance mechanisms in cancers like pancreatic cancer, triple-negative breast cancer, or glioblastoma – diseases notorious for their formidable immunosuppressive environments. This research from King’s College London marks a paradigm shift in cancer immunotherapy, moving beyond the well-trodden paths of IgG antibodies to unlock a powerful, previously underestimated, component of our immune system. It offers a renewed sense of hope and a tangible pathway towards more effective and durable treatments for patients desperately in need.
A Collaborative Effort
This groundbreaking work was made possible through the generous support of leading cancer research organizations, including Cancer Research UK, the Medical Research Council, and Breast Cancer Now. The authors also gratefully acknowledge the crucial support from the Cancer Research UK City of London Centre and the King’s Health Partners Centre for Translational Medicine, without which this pioneering research would not have been possible. The collaborative spirit demonstrated across multiple institutions and funding bodies underscores the collective determination to defeat cancer and improve patient lives worldwide.
About the Author
